Equity Profile

GILD

Gilead Sciences, Inc.

Health CareBiotechnology$171.3B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on discovering, developing, and commercializing innovative medicines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will show how well Gilead is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth indicates how effectively Gilead is expanding its market presence and product sales, which is crucial for future investments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GILD Q2-2026 Earnings Preview

Context

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on discovering, developing, and commercializing innovative medicines. Operating in the health care sector, Gilead is particularly known for its antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, making it a significant player in the fight against infectious diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

In Q1 2026, Gilead reported an EPS of $2.03, exceeding expectations by 7.69%. However, the stock experienced a slight decline of 1.64% the following day, indicating mixed market reactions despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Gilead's upcoming earnings report, especially given its consistent track record of beating EPS estimates. However, the lack of revenue guidance may lead to uncertainty in how the market will react.

Bull Case

If Gilead continues its trend of beating EPS estimates, it could signal strong operational performance and market confidence, potentially driving the stock higher.

Bear Case

Conversely, if Gilead fails to provide clear guidance or if there are signs of declining revenue, it could raise concerns about the company's growth trajectory and lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given Gilead's history of beating EPS estimates, this number will be critical in determining market sentiment and stock movement.

How will Gilead address revenue growth in the upcoming quarter?

Investors will be looking for clarity on revenue trends, as this will impact future growth expectations and overall confidence in the company's direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Gilead's ability to maintain its EPS growth, given its recent performance and product pipeline advancements.

Supporting Evidence

Gilead has consistently beaten EPS estimates, indicating strong operational management.

The options market is pricing in a 3.77% move, which is higher than the historical average, suggesting potential for a significant reaction.

Recent trends in the biotech sector show increasing demand for antiviral treatments, which could benefit Gilead.

Key Risk

If Gilead's EPS comes in below $1.90, it could undermine confidence in its growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Gilead's ability to sustain its earnings growth amidst competitive pressures and changing market dynamics.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $1.90 would raise concerns about Gilead's profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±3.77%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a move of approximately 3.77%, suggesting that traders expect some volatility around the earnings announcement.

Options are pricing ±3.8% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

22.3%

Calls (429K)P/C Ratio: 0.42Puts (148K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations, history suggests the stock could see an average one-day move of around 1.16%, confirming bullish sentiment.

In-Line / Cautious

A cautious in-line report could lead to muted reactions, as investors weigh management commentary against historical performance.

Miss

If Gilead misses expectations, history suggests a potential decline of around 1.16%, which could raise concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Insights into revenue growth strategies and potential challenges.
4Details on cost management and operational efficiencies.
5Guidance on future earnings expectations and market outlook.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on discovering, developing, and commercializing innovative medicines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will show how well Gilead is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth indicates how effectively Gilead is expanding its market presence and product sales, which is crucial for future investments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GILD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Gilead continues its trend of beating EPS estimates, it could signal strong operational performance and market confidence, potentially driving the stock higher.

Bear Case

Conversely, if Gilead fails to provide clear guidance or if there are signs of declining revenue, it could raise concerns about the company's growth trajectory and lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given Gilead's history of beating EPS estimates, this number will be critical in determining market sentiment and stock movement.

How will Gilead address revenue growth in the upcoming quarter?

Investors will be looking for clarity on revenue trends, as this will impact future growth expectations and overall confidence in the company's direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Gilead's ability to maintain its EPS growth, given its recent performance and product pipeline advancements.

Supporting Evidence

Gilead has consistently beaten EPS estimates, indicating strong operational management.

The options market is pricing in a 3.77% move, which is higher than the historical average, suggesting potential for a significant reaction.

Recent trends in the biotech sector show increasing demand for antiviral treatments, which could benefit Gilead.

Key Risk

If Gilead's EPS comes in below $1.90, it could undermine confidence in its growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Gilead's ability to sustain its earnings growth amidst competitive pressures and changing market dynamics.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $1.90 would raise concerns about Gilead's profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±3.77%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a move of approximately 3.77%, suggesting that traders expect some volatility around the earnings announcement.

Options are pricing ±3.8% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

22.3%

Calls (429K)P/C Ratio: 0.42Puts (148K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations, history suggests the stock could see an average one-day move of around 1.16%, confirming bullish sentiment.

In-Line / Cautious

A cautious in-line report could lead to muted reactions, as investors weigh management commentary against historical performance.

Miss

If Gilead misses expectations, history suggests a potential decline of around 1.16%, which could raise concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Insights into revenue growth strategies and potential challenges.
4Details on cost management and operational efficiencies.
5Guidance on future earnings expectations and market outlook.